A Dose Increase Finding Study of Doxorubicin Hydrochloride Liposome Injection for Patients With Breast Cancer

Inclusion Criteria

• •Female patients newly diagnosed breast cancer≥18 and ≤70 years of age;
• •Karnofsky performance status≥70 and measurable or evaluable;
• •Stages Ⅲa-ⅢC;
• •Baseline left ventricular ejection fraction (LVEF) ≥ 50%;
• •Adequate marrow function (WBC count\> 4.0×10(9)/L, neutrophil\> 2.0×10(9)/L, platelet count \> 100×10(9)/L，hemoglobin \> 90g/L );
• •AST and ALT ≤1.5× institutional upper limit of normal, alkaline phosphatase
• •≤2.5×institutional upper limit of normal，bilirubin ≤institutional upper limit of normal;
• •Serum creatinine ≥ 44µmol/L and ≤ 133 µmol/L;
• •Expected lifetime ≥ 12 months;
• •Pregnancy tests of reproductive age women is negative;
• •All patients provided written informed consent.